Shanghai Huilun Pharmaceutical reports new angiotensin AT2 receptor antagonists

Endpoints NewsFDA greenlights Colorado's drug import proposal

CellThe critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM

FierceBiotechPE firm Altaris scoops up AI drug development outfit Simulations Plus for $375M

BioPharma DiveLilly buys non-opioid pain drugmaker 4E

BioPharma DiveExpress Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies

BioWorldChinese challenger Gan & Lee gains momentum in metabolic disease

BioWorldElixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorldChina partnerships drive biopharma’s biggest deal month since 2023

BioWorldOricell brings first pivotal-stage CAR T in liver cancer

BioWorldLaekna licenses LAE-118 ex-China to Vasque in $527M deal

BioPharma DiveFDA staff scrutinizes evidence supporting Moderna’s flu vaccine

Endpoints NewsEdgewise to advance heart drug into Phase 3 following mid-stage data update